4-amino-2-chloro-benzoic acid chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-2-chloro-benzoic acid chloride
• 英文别名: 4-Amino-2-chlorobenzoyl chloride
• 化学式: C₇H₅Cl₂NO
• 分子量: 190.029
• InChiKey: YBMVYFGHCHJKMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-amino-2-chloro-benzoic acid chloride 在 palladium diacetate 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel 7H-benzo [c] [1, 3] dioxolo [4, 5-f] chromen-7-one derivatives with potential anti-tumor activity

  摘要：

  In this study, a series of novel 7H-benzo [c] [1,3] dioxolo [4, 5-f] chromen-7-one derivatives were obtained by structural modification of the lead compounds with Fissitungfine B. A total 15 compounds were designed, synthesized and evaluated as inhibitors of tumor. These target compounds have the novel chemical structures that named three six-membered rings including one lactone six-membered ring. In vitro assay, the results showed that the target compounds have a broad spectrum and strong of anti-tumor activity. Such as the target compound 4n to MCF-7 was IC₅₀ = 0.35 ± 0.01 μM, to A-549 was IC₅₀ = 0.37 ± 0.01 μM, to Hela was IC₅₀ = 0.56 ± 0.02 μM, to MDC-803 was IC₅₀ = 0.53 ± 0.02 μM and COLO-205 was IC₅₀ = 0.50 ± 0.02 μM in vitro. At the same time, in vivo anti-tumor activity assay results showed that the target compounds had a good inhibitory effect on tumor growth. Among them, the target compound 4n had the best anti-tumor activity, it could inhibit tumor growth well at a low dose. The target compound 4n could be used as a candidate drug for further research and development, in order to be used as early as application in the clinical treatment of tumors.

  DOI：

  10.1016/j.bioorg.2020.104381
• 作为产物：
  描述：

  2-氯-4-硝基苯甲酰氯 在 氢气 作用下， 以 乙醇 为溶剂， 120.0 ℃ 、2.0 MPa 条件下， 反应 3.0h， 生成 4-amino-2-chloro-benzoic acid chloride
  参考文献：
  名称：

  用于卤代硝基芳烃选择性加氢的高效且可回收的双金属 Co-Cu 催化剂

  摘要：

  通过一步浸渍 Co(NO 3 ) 2 ·6H 2 O、Cu(NO 3 ) 2 ·制备二氧化硅负载的 N 掺杂碳层，包覆 Co-Cu 纳米颗粒 (Co 1 Cu x @CN/SiO 2 ) 3H 2 O、尿素和葡萄糖，在原位碳热还原之后。研究了Cu含量对Co 1 Cu x @CN/SiO 2催化剂催化对氯硝基苯选择性加氢制备对氯苯胺的催化性能的影响。Co 1 Cu 0.30 @CN/SiO2 0.30的Cu / Co的摩尔比：1中呈现高得多的活性和稳定性比单金属钴@ CN /二氧化硅2催化剂。在 Co 1 Cu x @CN/SiO 2催化剂中加入 Cu对高活性 Co-N 位点和 N 掺杂碳层的形成有有利的影响。N掺杂碳层的作用是保护Co免受空气氧化，Co 1 Cu 0.30 @CN/SiO 2可以重复使用至少 12 个循环而不会降低催化效率。机理和原位红外研究表明，Co 和 Cu 原子之间的相互作用使

  DOI：

  10.1016/j.jallcom.2021.163143

文献信息

• Benzoheterocyclic derivatives
  申请人：Otsuka Pharmaceuticals Co., Ltd.

  公开号：US06335327B1

  公开（公告）日：2002-01-01

  A benzoheterocyclic derivative of the following formula [1]: and pharmaceutically acceptable salts thereof, which show excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as a vasopressin antagonist, vasopressin agonist or oxytocin antagonist.

  以下是该句子的中文翻译： 一种苯并杂环衍生物，其化学式如下： 及其药用盐，表现出优异的抗加压素活性、加压素激动活性和催产素拮抗活性，可用作加压素拮抗剂、加压素激动剂或催产素拮抗剂。
• Microwave assisted synthesis of phenanthridinones and dihydrophenanthridines by vasicine/KOtBu promoted intramolecular C–H arylation
  作者：Sushila Sharma、Manoranjan Kumar、Shruti Sharma、Onkar S. Nayal、Neeraj Kumar、Bikram Singh、Upendra Sharma

  DOI：10.1039/c6ob01362g

  日期：——

  simple, efficient, rapid and transition metal-free methodology has been developed by utilizing vasicine (a natural product), as a catalyst for the synthesis of phenanthridinones and dihydrophenanthridines. The reaction proceeds through intramolecular C–H arylation with aryl halides in the presence of KOtBu as a base under microwave irradiation in sulfolane as a solvent. The reaction proceeds well with various

  已经开发了一种简单，有效，快速且无过渡金属的方法，该方法通过利用vasicine（天然产物）作为合成菲啶酮和二氢菲啶的催化剂。通过分子内C-H芳基化反应的进行，在KO的存在下芳基卤化物吨卜如在环丁砜微波辐射下碱作为溶剂。该反应在使用各种芳基碘，溴化物的情况下进行得很好，而在反应性较低的芳基氯化物下反应则更为显着，持续15分钟，从而以45-90％的收率提供了相应的产物。
• Amino-benzoic acid amides
  申请人：Boehringer Ingelheim GmbH

  公开号：US04093734A1

  公开（公告）日：1978-06-06

  Compounds of the formula ##STR1## wherein (A) WHEN THE AMINO-SUBSTITUENT IS IN THE P-POSITION WITH RESPECT TO THE CARBONYL GROUP, R.sub.1 is chlorine in the o-position with respect to the carbonyl group, R.sub.2 is hydrogen, and R.sub.3 is ethylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, N-methyl-cyclohexylamino, benzylamino or 1-ethyl-pyrrolidyl-(2)-aminomethyl, or (b) when the amino-substituent is in the o--, m-- or p-position with respect to the carbonyl group, R.sub.1 is hydrogen, chlorine or bromine, R.sub.2 is trifluoromethyl, nitro or, when R.sub.4 is 1-(alkyl of 1 to 3 carbon atoms)-pyrrolidyl or 1-(alkyl of 1 to 3 carbon atoms)-piperidyl, also fluorine, chlorine, bromine or methyl, R.sub.3 is (alkyl of 1 to 5 carbon atoms)-amino, (cycloalkyl of 3 to 7 carbon atoms)-amino, benzylamino, quinuclidinyl-amino or --NH--(CH.sub.2).sub.n --R.sub.4 where R.sub.4 is pyridyl, 1-(alkyl of 1 to 3 carbon atoms)-pyrrolidyl, 1-(alkyl of 1 to 3 carbon atoms)-piperidyl or, when n is 2 or 3, also imidazolonyl, pyrrolidino, piperidino or morpholino, and n is 0, 1, 2 or 3, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as anxiolytics, anticonvulsives, antiemetics and antiulcerogenics.

  式为##STR1##的化合物，其中（a）当氨基取代物位于与羰基相对的p-位置时，R.sub.1是与羰基相对的o-位置的氯，R.sub.2是氢，R.sub.3是乙基氨基，环戊基氨基，环己基氨基，环庚基氨基，N-甲基环己基氨基，苄氨基或1-乙基吡咯啉基（2）-氨基甲基；或（b）当氨基取代物位于与羰基相对的o-、m-或p-位置时，R.sub.1是氢，氯或溴，R.sub.2是三氟甲基，硝基或者当R.sub.4是1-（含1至3个碳原子的烷基）-吡咯啉基或1-（含1至3个碳原子的烷基）-哌啶基时，也可以是氟、氯、溴或甲基，R.sub.3是（含1至5个碳原子的烷基）-氨基，（含3至7个碳原子的环烷基）-氨基，苄氨基，喹啉基氨基或--NH--（CH.sub.2）.sub.n --R.sub.4，其中R.sub.4是吡啶基，1-（含1至3个碳原子的烷基）-吡咯啉基，1-（含1至3个碳原子的烷基）-哌啶基或者当n为2或3时，也可以是咪唑基，吡咯啉基，哌啶基或吗啉基，n为0、1、2或3。以及其非毒性、药理学上可接受的酸盐；这些化合物及其盐可用作抗焦虑药、抗抽搐药、抗恶心药和抗溃疡药。
• AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR
  申请人：SEIKA CORPORATION

  公开号：US20180079732A1

  公开（公告）日：2018-03-22

  A novel asymmetric diamine, diamino-2-(benzothiazole-2-yl)diphenyl ether, derivatives therefor, and an intermediate for the compound such as aminonitro-2-(benzothiazole-2-yl)diphenyl ether, dinitro-2-(benzothiazole-2-yl)diphenyl ether, and derivatives from these. Additionally, another novel asymmetric diamine, diamino-2-(benzoxazole-2-yl)diphenyl ether, derivatives therefor, and intermediate for the compound such as aminonitro-2-(benzoxazole-2-yl)diphenyl ether, dinitro-2-(benzoxazole-2-yl)diphenyl ether, and derivatives from these, and methods for preparing them.

  一种新型的不对称二胺，二氨基-2-(苯并噻唑-2-基)二苯醚，以及其衍生物，以及该化合物的中间体，如氨基硝基-2-(苯并噻唑-2-基)二苯醚，二硝基-2-(苯并噻唑-2-基)二苯醚，以及从中得到的衍生物。此外，另一种新型的不对称二胺，二氨基-2-(苯并噁唑-2-基)二苯醚，以及其衍生物，以及该化合物的中间体，如氨基硝基-2-(苯并噁唑-2-基)二苯醚，二硝基-2-(苯并噁唑-2-基)二苯醚，以及从中得到的衍生物，以及其制备方法。
• Novel oxadiazole compounds
  申请人：Hobson Adrian D.

  公开号：US20080280876A1

  公开（公告）日：2008-11-13

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  本发明揭示了新型噁二唑化合物、含有该化合物的药物组合物以及将这些化合物或组合物用作S1P家族G蛋白偶联受体的激动剂或拮抗剂，用于治疗与S1P家族受体活性调节相关的疾病，特别是通过提供有益的免疫抑制效应的疾病。